EPHA2 and carcinoma: Overexpression of ephrins A1 and A5 in EOC was associated with poor survival [26]; Ephrin B1 expression was associated with high-grade carcinomas and microvessel density as well as higher rates of disease recurrence and poor overall survival [25]; EphB4/ephrinB2 expression level was increased with increased clinical stages and higher EphB4/ephrinB2 expression was associated with poor survival [24]; and silencing both EphA2 and EphB2 by siRNA has synergetic antitumor effect [22].